Dapagliflozin did not significantly reduce organ failure or death in high-risk patients hospitalized with COVID-19
Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing ...
May 17, 2021
0
3
